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ROLE OF POLYMORPHIC Fc RECEPTOR FcyRIIa IN CYTOKINE 
BFTBASW AND ADVERSE EFFECTS OF MURINE IgGl ANTI-CDOT 
CELL RECEPTOR ANTIBODY (WT3X)1
W il J.M. Tax ,2 Wim P.M. Tambobr, C or W.M. Jacob s, L eon  A.M. F renken , and
Robert A .P. Koene
Department of Medicine, Division of Nephrology, University Hospital Nijmegen, 6500 HB Nijmegen1 The Netherlands
Anti-CD3 monoclonal antibody (mAb) OKT3 is im­
munosuppressive, but causes severe adverse effects 
during the first administration (“first-dose reaction”)« 
These adverse effects are presumably caused by cyto­
kine release that results from T-cell activation. In 
vitro, T-cell activation by anti-CD3 mAb requires in­
teraction with monocyte Fc receptors. The Fc receptor 
for murine IgGl, FcyRIIa, is polymorphic. In some 
individuals, murine IgGl anti-CDS mAb causes T-cell 
proliferation and cytokine release in vitro (high re­
sponders [HR]), whereas in individuals with the low- 
responder (LR) phenotype it does not. We have now  
investigated the role of this FcyRIIa polymorphism in 
the release of cytokines in vivo and the occurrence of 
adverse effects after the administration of WT31, a 
murine IgGl anti-CD3/T cell receptor mAb. WT31 
caused an increase of plasma tumor necrosis factor-a 
in all four HR patients and none of the five LR pa­
tients. In all HR patients except one, plasma y-inter- 
feron and interleukin 6 also increased, and a first-dose 
response was observed, whereas no cytokine release 
or adverse effects occurred in any of the LR patients. 
WT31 caused lymphopenia in all HR and none of the 
LR patients. FACS analysis demonstrated that in HR 
patients, after the initial disappearance of CD3+ cells 
from peripheral blood, modulation of CD3 occurred, 
whereas in LR patients a high degree of coating of the 
lymphocytes was observed. Surprisingly, WT31 also 
induced a marked granulocytopenia, as well as a de­
crease of thrombocytes, in three of the four HR pa­
tients (and in none of the LR patients). These data 
provide direct clinical evidence that Fc receptor inter­
action determines the release of cytokines and the 
occurrence of adverse effects after administration of 
anti-CD3/T cell receptor mAb* Furthermore, these data 
suggest that tumor necrosis factor-a by itself is not 
sufficient to induce the first-dose reaction.
Monoclonal antibodies (mAb*) against the T cell antigen 
CD3 can be immunosuppressive during transplant rejection 
episodes, as illustrated by the mAb OKT3. The first admin­
istration of OKT3, however, usually evokes severe adverse 
effects that presumably are related to a massive release of
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Netherlands Academy of Arts and Sciences.
2 Address correspondence to: W.J.M. Tax, PhD, Department of 
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* Abbreviations: HR, high responder; IFN-y, 7-interferon; IL, in­
terleukin; LR, low responder; m, murine; mAb, monoclonal antibody; 
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cytokines in vivo. High serum levels of tumor necrosis fac­
tor-« (TNFa), y-interferon (IFN-y), and, to a lesser extent, 
interleukin (IL) 2 are observed a few hours after the first 
injection, presumably resulting from T-cell activation in vivo 
(1-3). Previous studies have demonstrated that in vitro T-cell 
activation and proliferation induced by anti-CD3 mAb are 
dependent on the presence of monocytes bearing Fey recep­
tors that bind murine IgG (4> 5). Different human Fey recep­
tors are involved in the binding of murine IgG, depending on 
the isotype of the antibody. Murine (m) IgG2a antibodies 
such as OKT3 interact with human FcyRI, whereas the Fey 
receptor responsible for binding of mlgGl is FcyRIIa, an 
isoform of FcyRII that occurs on monocytes, macrophages, 
granulocytes, and thrombocytes (6). FcyRIIa is known to be 
polymorphic: mlgGl anti-CD3 mAb induces (monocyte-de­
pendent) T-cell proliferation in vitro in only 70% of normal 
Caucasian individuals (high responders [HR]), but not in 
low-responder (LR) individuals (4, 5). This genetic polymor­
phism of FcyRIIa is also reflected in the release of cytokines 
(IFN-y and IL-2) observed in vitro when mononuclear cells 
are incubated with mlgGl anti-CD3 mAb (7).
Murine IgGl anti-CD3 mAb have not yet been tested in 
vivo for their immunosuppressive effect and adverse effects, 
In LR patients, the adverse effects might be milder or even 
absent. If at the same time the immunosuppressive effect 
would be independent of interaction with Fey receptors, such 
an anti-CD3 mAb might provide (at least in LR patients) 
immunosuppression without serious adverse effects (8). The 
present study was set up primarily to investigate whether 
WT31, an mlgGl mAb directed against the CD3-associated T 
cell receptor (TCR), induces the release of cytokines in vivo 
and the cytokine-associated “first-dose reaction” more fre­
quently in those patients whose FcyRIIa can bind mlgGl 
(HR) than in LR patients.
MATERIALS AND METHODS
Monoclonal antibody WT31. WT31 is an mlgGl mAb developed in 
our laboratory and is directed against the CD3-associated TCR {9t 
10). The large-scale production of WT31 and its purification from 
culture supernatant were performed at the Dutch National Institute 
of Public Health and Environmental Protection, as described else­
where {11).
Determination o f FcyRIIa phenotype and genotype. To determine 
whether patients to be treated with WT31 were HR or LR, T-cell 
proliferation induced by WT31 in vitro was measured (4). The 
FcyRIIa genotype was also determined by analysis of genomic DNA, 
essentially as described by Osborne et al. (12). Brieflyt DNA was 
extracted from peripheral blood cells and amplified by polymerase 
chain reaction. Polymerase chain reaction amplification products
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were then separated on agarose gel, blotted, and hybridized first 
with an oligonucleotide specific for the LR allele and then, after 
stripping, with an oligonucleotide specific for the HR allele. The 
sequences of the allotype-specific oligonucleotides have been pub­
lished (12). Polymerase chain reaction products from cell lines U937 
(homozygous HR) and K562 (heterozygous) were included as con­
trols.
Treatment with WT31. This study was approved by the institu­
tional ethical committee, and informed consent was obtained from all 
patients. WT31 was administered by intravenous infusion to nine 
patients with a rejection episode after kidney transplantation. The 
diagnosis of rejection was made using clinical criteria, and confirmed 
by histology of allograft biopsy (except in LR patient 4, for whom no 
biopsy could be performed). Four patients were HR, and five were 
LR. All LR patients received 6 mg of WT31 on the first day of 
treatment. The first HR patient also received an initial dose of 6 mg, 
but in view of the severe side effects (see below), the initial dose 
administered to the other three HR patients was 1 mg of WT31. 
Furthermore, corticosteroids (50 mg of intravenous prednisolone 1 hr 
before WT31 administration) were given to all HR patients except 
the first one. The same premedication was given to the first LR 
patient treated with WT31, but not to the other LR patients.
Monitoring of patients. Monitoring of adverse effects (clinical 
symptoms included fever, chills, dyspnea, nausea, diarrhea, and 
headache) was performed at regular intervals after each dose of 
WT31.
Plasma was obtained from blood samples collected in EDTA tubes 
before and during the first hours after the First administration of 
WT31, by immediate centrifugation at 4°C, and aliquots were stored 
at -70°C until tested. An immunoradiometric assay was used to 
measure TNFa, IFN-y, IL-6, and IL-2 (Medgenix Diagnostics, Fleu- 
rus, Belgium).
Production of human antibodies against WT31 was measured by 
analyzing serum samples in an ELISA.
Differential cell counts of peripheral blood were made before the 
first administration of WT31, during the first hours after starting 
WT31, and then daily. Lymphocyte subsets were determined daily, 
using direct immunofluorescence with anti-CD3 (anti-Leu-4), anti- 
CD4 (anti-Leu-3a), anti-CD8 (anti-Leu-2a), and anti-TCR (WT31) 
mAb labeled with phycoerythrin or fluorescein (Becton Dickinson, 
Mountain View, CA). Cells were also stained with fluorescein iso- 
thiocyanate-labeled anti-mouse Ig to evaluate the amount of murine 
antibody bound in vivo to the lymphocytes (“coating”). Flow cytom­
etry was performed using a Coulter Epics Elite (Coulter Corp., Hi­
aleah, FL).
Statistics. The hypothesis that WT31 would cause more cytokine 
release and cytokine-related adverse effects in HR patients was 
tested statistically by calculating one-tailed P-values in the Fisher 
exact probability test.
RESULTS
Responder status of WT31 patients. The responder status 
of patients to be treated with WT31 was initially determined 
by the T-cell proliferation assay. Individuals with an HR 
phenotype may be either heterozygous or homozygous geno­
typically. Recently, a method was described for analysis of 
the genotype using allele-specific oligonucleotides. This 
method was applied to DNA obtained from peripheral blood 
cells from all patients who had been treated with WT31 
(except LR patient 3 from whom no cellular material was 
available). As shown in Figure 1, the results from this geno- 
typing confirmed the responder status determined by the 
T-cell proliferation assay. Furthermore, all HR patients were 
found to be heterozygous.
Clinical adverse effects ofWT31 in HR patients. Adminis­
tration of WT31 (6 mg) to the first patient treated with WT31
1 2 3 4 5  6 7 8 9  10 11
F igu re  1. Genotyping of patients treated with WT31. DNA from 
peripheral blood cells was isolated and amplified by polymerase 
chain reaction. Southern blots obtained after agarose electrophoresis 
were then hybridized with oligonucleotides specific for the HR allele 
(a) or LR allele (b) of the FcyRIIA gene. Lane 1: water; lane 2: U937 
(homozygous HR); lane 3: K562 (heterozygous HR); lanes 4-7: HR 
patients 4, 3, 2, and 1; lanes 8-11: LR patients 2, 1, 4, and 5.
(HR patient 1 ) induced a clear-cut first-dose reaction, includ­
ing high fever and chills, starting approximately 45 min after 
the start of the infusion. These side effects, and the low 
numbers of granulocytes and thrombocytes (see below), ne­
cessitated the interruption of WT31 treatment in this patient 
for several days. In view of the observed side effects, the other 
HR patients received a much lower initial dose (1 mg) of 
WT31, and prednisolone as premedication. Despite this, all 
HR patients except HR patient 2 had a first-dose response 
(although to a lesser extent than the first HR patient). One 
HR patient (patient 2) had some symptoms of the cytokine- 
related syndrome, but only on the day after the start of WT31 
and not immediately afterward. In complete contrast, none of 
the five LR patients showed any sign of first-dose reaction, 
despite the fact that the first dose of WT31 was 6 mg and four 
of these patients had received no premedication with corti­
costeroids. Higher doses of WT31 (up to 30 mg/day) were 
given to two LR patients later during treatment, and these 
high doses were also tolerated very well.
Effect of WT31 on lymphocytes, granulocytes, and throm­
bocytes. Administration of WT31 induced an immediate and 
large decrease of lymphocytes (to values below 150//xl) in all 
HR patients, as illustrated for HR patient 4 in Figure 2À. 
Only a slight and transient decrease of lymphocytes occurred 
in LR patient 2 (maximal percent decrease after the first dose 
was 36%). In the other LR patients, the percent decrease of 
lymphocytes was 18% or less, as illustrated for LR patient 1 
in Figure 2B.
In three of the HR patients, WT31 also induced a profound 
granulocytopenia (Fig. 2A). This granulocytopenia necessi­
tated the interruption of WT31 treatment for 1  or several 
days in these patients. In HR patient 2, the number of gran­
ulocytes decreased only marginally. Although there were 
day-to-day fluctuations in the number of granulocytes, there 
was no consistent decrease of granulocytes in any of the LR 
patients, as illustrated for LR patient 1  in Figure 2 B.
In HR patient 1 , the number of thrombocytes (which was 
already low at the start of WT31 therapy) decreased further, 
and remained very low for several days. In the other HR 
patients, there was a short-lasting and modest decrease of 
thrombocytes (maximal percent decrease was 24%, 30%, and 
14%). No decrease of thrombocytes was observed in LR pa­
tients.
Effect ofWT31 on rejection episode. In HR patient 1 , WT31 
treatment had to be interrupted for several days because of
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Figure 2, Total number of lymphocytes (À) and granulocytes (■) 
during WT31 treatment of HR patient 4 (A) and LR patient 1 (B). 
Cells were counted daily before, during WT31 treatment, and a few 
hours after each administration of WT31.
profound granulocytopenia, as mentioned above. For the 
same reason, also in HR patient 4 only a few (low) doses of 
WT31 could be given (Fig, 2À). In the two HR patients to 
whom WT31 could be administered without interruptions, 
kidney function improved. In HR patient 2, serum creatinine 
decreased from 307 p,mol/L before treatment to 163 ptmol/L 
after the last dose of WT31. In HR patient 3, serum creati­
nine also decreased during WT31 treatment, as illustrated in 
Figure 3À. In the first two LR patients, we found no indica­
tions for an immunosuppressive effect of WT31, as illustrated 
for LR patient 1 in Figure 3B, Because of these results, and 
because the main interest was to study the cytokine-associ­
ated adverse effects in relation to the Fc7RIIa polymorphism, 
it was decided to treat the following LR patients after the 
first dose of WT31 with additional immunosuppression (an­
tithymocyte globulin, high-do se prednisolone, or anti-CD 3 
mAh WT32),
FACS analysis of peripheral lymphocytes. In HR patients, 
the WT31-induced disappearance of lymphocytes described 
above was also reflected in a strong decrease in the percent­
ages of CD3+ cells and CD4+ cells. This is illustrated in 
Figure 4 for HR patient 3 (who received daily injections of 
WT31 during 10 days except on day 3). For CD8+ cells, a 
similar decrease was observed (data not shown). After this
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F igu re 3, Serum creatinine during WT31 treatment of HR patient 3 
(A) and LR patient 1 (B). On the x axis, the number of days before or 
after the start of WT31 treatment is indicated. In the HR patient, 
WT31 appeared to be effective. In the LR patient, serum creatinine 
continued to rise despite an increased dose of WT31, and antithymo- 
cyte globulin (ATCr) was then administered, resulting in a decrease of 
creatinine.
blood, the percentages of CDS4' cells, CD4+ cells, and CD8+ 
cells increased again. The intensity of the CD3 staining, 
however, was about threefold lower during these final days of 
WT31 treatment than before treatment (the intensity of CD4 
or CD8 staining did not change).
In LR patients, there was no decrease in the percentages of 
cells staining with anti-CD3 or anti-CD4 (Fig. 4), or anti- 
CD8. The intensity of staining with anti~CD4 and anti-CD8 
antibodies remained at the same level, and there was only a 
slight decrease in the intensity of anti-CD3 staining. There 
was, however, a marked increase in the degree of coating of 
mononuclear ceils from LR patients during WT31 treatment, 
whereas coating was virtually absent in HR cells (Fig. 5).
Cytokine release induced in HR patients. In plasma sam­
ples obtained from HR patient 1  during the first hours after 
the start of WT31, very high concentrations of circulating 
cytokines were measured. Peak values were 1750 pg/ml for 
TNFa, 7600 pg/ml for IL-6, 10.4 IU/ml for IFN-% and 2.2 
IU/ml for IL-2 (pretreatment values were 66 pg/ml, 16 pg/ml, 
0.6 IU/ml, and 0.5 IU/ml, respectively). An increase of TNFa 
was measured in plasma samples from all HR patients but 
not in any of the five LR patients (Fig, 6). It is noteworthy 
that peak levels of TNFa of these HR patients were much 
lower than the level measured in the first HR patient who 
received a higher dose of WT31 and no premedication. No 
increase of IFN-y was observed in the five LR patients, 
whereas increased concentrations were measured in all HR
initial phase of disappearance of T cells from peripheral patients except the one who showed no immediate first-dose
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F igu re  4. Percentage of CD3+ or CD4+ lymphocytes during WT31 
treatment of HR patient 3 (solid lines) and LR patient 2 (dashed 
lines): percentage of CD3+ cells in HR patient (•) and LR patient (O); 
percentage of CD4+ cells in HR patient (■) and LR patient (□). As 
described in the text, the expression of CD3 on recurring CD3+ 
lymphocytes of the HR patient was strongly decreased when com­
pared with the pretreatment value.
response (Fig. 7). Similar data as for IFN-7  were also ob­
tained for IL-6 (data not shown). With respect to IL-2, an 
increase of serum concentration was observed only in HR 
patient 1 .
Table 1 summarizes the results with respect to cytokine 
release and adverse effects in HR and LR patients.
Formation of anti-WT31 antibodies. Human antibodies 
against WT31 were found in sera from some but not all 
patients: LR patient 2, HR patient 1, HR patient 2 , and (at a 
low level) HR patient 3. Their presence, therefore, was not 
correlated with the Fc receptor polymorphism.
DISCUSSION
It has previously been suggested that Fc receptor interac­
tion is responsible for the “first-dose effect” of anti-CD3 mAb, 
This hypothesis was mainly based on the results of experi­
ments in the mouse model, e.g., studies with F(ab% anti- 
CD 3 (13) or with anti-CD3 combined with anti-FcR antibod­
ies (14). This study was set up primarily to test the 
hypothesis that in HR patients WT31 would cause more 
cytokine release and cytokine-related adverse effects than in 
LR patients. Our results clearly demonstrate that cytokine
MFI
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Days after first W T31
F igu re 5. Coating of lymphocytes in vivo after administration of 
WT31 to HR patients (solid lines) and LR patients (dashed lines). 
Mean fluorescence intensity (MFI) in arbitrary units is indicated on 
the y axis (• , HR patient 2; ■> HR patient 3; O, LR patient 1; □ , LR 
patient 2).
release and adverse effects indeed correlate with the pres­
ence of the HR allele of Fc7RIIa, Increased values of plasma 
TNFa were measured in all four HR patients, and in three 
HR patients there was also an increase of IFN-7  and IL-6, 
and a clinical first-dose effect. No adverse effects and no 
cytokine was observed in any of the five LR patients. The 
complete absence of TNFa: release in LR patients confirms 
that the antibody preparation is free of endotoxin (known to 
be a potent inducer of TNFa [15]).
It is remarkable that one of the HR patients (HR patient 2) 
showed no immediate side effects of WT31 administration 
(although some adverse effects, including fever and myalgia, 
were observed on the second day of treatment). The cause for 
this discrepancy with the other HR patients is not entirely 
clear. The number of CD3+ cells in peripheral blood before 
treatment was similar to that of other HR patients. It may be 
relevant that, in contrast to the other patients, this patient 
was treated with WT31 soon after the transplantation (with­
in the first month). At this time he received still high doses of 
basic immunosuppression, including prednisolone, which 
may have dampened cytokine release and side effects. In this 
patient there was an increase of plasma TNFa, but no in­
creased IFN-7  or IL-6. These findings are reminiscent of 
those obtained by Chatenoud et al. (16), who observed only
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Figure 6. Plasma TNFa during the first hours after the first admin­
istration of WT31 to HR patients (solid lines) and LR patients 
(dashed lines) (•, HR patient 2; ■, HR patient 3; A, HR patient 4; □,
LR patient 1; A, LR patient 2 ;......... , LR patient 3; ***, LR patient
4; O, LR patient 5), Tn HR patient 1 (not included in the Figure), peak 
value for TNFa was about fourfold higher than in HR patient 3 or HR 
patient 4 (see text).
IFN-gamma
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F igu re  7, Plasma IFN-y during the first hours after the first admin­
istration of WT31 to HR patients (solid lines) or LR patients (dashed 
lines) (• , HR patient 2; ■, HR patient 3; À, HR patient 4; □ , LR
patient 1; A, LR patient 2 ;-------, LR patient 3; ***, LR patient 4; O,
LR patient 5). In HR patient 1 (not included in the Figure), peak 
value for IFN-y was about fourfold higher than in HR patient 3 or HR 
patient 4 (see text).
mild or no side effects after administration of BMA031 (an 
mIgG2b anti-TCR mAb) despite a sharp increase of TNFa 
but not IFN-y. Similar results were obtained with an mlgA 
anti-CD3 mAb: TNFa but not IFN-y increased, and adverse 
effects were significantly less than those observed with an 
mIgG2a of precisely the same specificity that induced both 
TNFa and IFN-y (17). Apparently in addition to TNFa, IFN-y 
is required to induce the characteristic first-dose reaction. 
This hypothesis is supported by the protective effect of anti- 
IFN-y antibodies on anti-CD3-induced morbidity and mortal­
ity in mice (18),
The polymorphism of FcyRIIa was also reflected in the 
disappearance of lymphocytes from peripheral blood after the 
first dose of WT31, which occurred in all of the HR patients 
and none of the LR patients. In LR patients we also found no 
evidence for a transient lymphopenia during the first hours 
after administration of the antibody, as was seen with an 
mlgA anti-CD3 mAb (17). In a recent study it was demon-
T ab le  1. Cytokine release and first-dose reaction after the first
administration of WT31 to HR and LR patients®
HR LR P
Increase of TNFa 4/4 0/5 < 0.01
Increase of IFN-y 3/4 0/5 <0.05
Increase of IL-6 3/4 0/5 <0.05
First-dose reaction 3/4 0/5 <0.05
Lymphocytopenia 4/4 0/5 < 0.01
Gr anulocytopenia 3/4 0/5 <0.05
a Statistical significance was tested using the one-tailed Fisher 
exact probability test,
strated that in vitro mlgA anti-CD3 induced T-cell adhesion 
to endothelium, whereas for WT31 this was observed only 
with HR cells and not with LR cells (S. Buysmann, Academic 
Medical Center, Amsterdam, The Netherlands, personal 
communication 1996). It is conceivable that in HR patients 
this increased T-cell adhesion has contributed to the initial
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decrease of peripheral T cells. The disappearance from pe­
ripheral blood of CD3+ cells caused by WT31 in HR patients
only is consistent with published data obtained in patients 
treated with an mlgGl anti-CD8 antibody showing that the 
CD8+ cells disappeared from peripheral blood only in HR 
patients (19). In humans, the disappearance of lymphocytes 
from peripheral blood induced by mlgGl antibodies appar­
ently requires FcR interaction. This contrasts with the find­
ings in mice, where such a disappearance of lymphocytes 
occurs after administration of F(ab')2 fragments of anti-CD3 
or anti-TCR antibodies (13> 20). One should be careful in 
extrapolating the results obtained in animal studies to the 
clinical situation. The outcome of treatment with a monoclo­
nal antibody will presumably depend on many factors, in­
cluding species, the affinity of the antibody, and its specific­
ity.
The disappearance of CD3+ lymphocytes from peripheral 
blood of HR patients was confirmed by FACS analysis. One 
should keep in mind that in HR patients only the very small 
number of T lymphocytes that have not disappeared from the 
peripheral blood is involved in this FACS analysis. Even 
among this strongly decreased number of lymphocytes, the 
percentage of CD3+ cells decreased to approximately 20% or 
less. Furthermore, the intensity of immunofluorescence per 
lymphocyte was about fourfold lower than pretreatment val­
ues. This decreased CD3 intensity of HR cells can only for a 
small part be ascribed to coating of the cells with the anti- 
TCR antibody WT31, since in LR patients the degree of cell 
coating was much higher, and in these LR patients only a 
slight decrease of CD3 intensity was observed. We have pre­
viously reported that in vitro WT31 can only partly inhibit 
the binding of anti-CD3 mAbs (9). The most likely explana­
tion of the decreased intensity of CD3 staining in HR patients 
is modulation of CD3/TCR from the cell surface after in vivo 
binding of WT31. The antigenic modulation apparently was 
not complete, since with the anti-Leu-4 antibody we could 
still detect a low-intensity staining on some T lymphocytes. 
This pattern (initial disappearance of T cells, followed by a 
period of CD3 modulation) is similar to that obtained with
mIgG2a mAb OKT3 (21) and WT32 (22).
In LR patients, we observed virtually no disappearance of 
CD3+ cells from peripheral blood, or modulation of CD3. The 
most striking feature of the FACS analysis in the LR patients 
was the very high degree of coating of lymphocytes with the 
WT31 antibody. This finding further underscores that the 
HR allele of FcyRIIa is required for the disappearance of T 
cells from peripheral blood induced by mlgGl mAb. In HR 
patients, most of the few T lymphocytes that remained 
present were also coated with WT31, but the degree of coat­
ing per lymphocyte was much lower than with LR cells.
A remarkable finding in the present study was the pro­
found and long-lasting granulocytopenia in HR patients after 
administration of WT31. In a previous study with mIgG2a, 
anti-CD3 mAb WT32 granulocytopenia was not observed (as 
a matter of fact, granulocytosis occurred [22]). Immediately 
after administration of OKT3, a modest decrease (approxi­
mately 40%) of granulocytes has been described, but this 
decrease was transient and granulocyte counts returned to 
normal values within 1 hr (23), The differential effects on 
granulocytes of WT31 versus OKT3 and WT32 may be re­
lated to the fact that mlgGl interacts with another human Fc
receptor than mIgG2a (FcyRIIa and FcyRI, respectively), and 
that FcyRIIa but not FcyRI is present on granulocytes. The 
disappearance of granulocytes may be caused by an in­
creased adhesion to endothelium, resulting from triggering of 
granulocyte FcyRIIa or perhaps mediated by WT31-induced 
granulocyte-macrophage colony-stimulating factor (24, 25). 
An alternative explanation is that in HR patients WT31 
activates T cells to kill granulocytes, since anti-CD3/TCR 
mAb can induce nonspecific cytotoxicity against target cells 
that express the appropriate Fey receptor (26).
WT31 also caused a decrease of thrombocytes in HR pa­
tients. Again, such a decrease has not been observed with 
mIgG2a antibodies OKT3 or WT32. FcyRIIa (but not FcyRI) 
is present on thrombocytes. In a patient with B cell leukemia 
who was treated with an mlgGl anti-idiotype mAb, a de­
crease of thrombocytes also occurred, presumably as a result 
of the binding of immune complexes containing mlgGl to 
FcyRIIa on the thrombocytes (27).
Anti-WT31 antibodies were present in serum of some but 
not all WT31-treated patients. Their presence did not corre­
late with the FcyRIIa polymorphism, although more patients 
in the HR group exhibited a humoral immune response to the 
mAb, This might be related to the fact that most of the HR 
patients received WT31 doses over a more prolonged period 
than the LR patients.
It is still uncertain whether interaction with Fc receptors is 
required for the immunosuppressive effects of anti-CD3 mAb 
in humans. In the two HR patients to whom WT31 could be 
administered without interruptions, kidney function im­
proved, whereas in the first two LR patients we found no 
indications for an immunosuppressive effect of WT31, de­
spite the fact that the WT31 dose was increased to 12 mg or 
even 30 mg. We realize that the number of patients is too 
small to draw any definitive conclusions from the present 
data with respect to the immunosuppressive potential of 
WT31. A tentative conclusion, however, might be that WT31 
may not be immunosuppressive in LR patients but it may be 
immunosuppressive in HR patients. If this is true, it would 
imply that FcR interaction plays a role not only in the ad­
verse effects but also in the immunosuppressive mechanism.
We recently reviewed the possible clinical significance of 
the polymorphism of human Fc receptors for immunotherapy 
(8). The data presented here clearly demonstrate that the 
FcyRIIa polymorphism defined by in vitro experiments in­
deed has direct implications for the in vivo use of mlgGl 
mAb, and provide direct clinical evidence that the occurrence 
of adverse effects of anti-CD3/TCR antibodies is correlated 
with the presence of an Fc receptor that can interact with the 
mAb. It is hoped that the knowledge obtained from pilot 
studies such as the present one can be helpful in designing 
suitably modified antibodies that combine optimal efficacy 
with minimal toxicity (28).
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